Advertisement
Advertisement
CTOR
Citius Oncology, Inc. Common Stock
1.05
USDSponsored
+0.04
+3.96%
Sep 24, 15:55 UTC -4
Closed
Pre-Market
0.97
-0.08
-7.14%
CTOR Earnings Reports
Positive Surprise Ratio
CTOR beat 3 of 7 last estimates.
43%
Next Report
Date of Next Report
Dec 21, 2026
Estimate for Q4 26 (Revenue/ EPS)
$5.89M
/-$0.21
Implied change from Q3 26 (Revenue/ EPS)
+294.00%
/+162.50%
Implied change from Q4 25 (Revenue/ EPS)
--
/+250.00%
Citius Oncology, Inc. Common Stock earnings per share and revenue
On Aug 14, 2026, CTOR reported earnings of -0.08 USD per share (EPS) for Q3 26, beating the estimate of -0.08 USD, resulting in a 1.96% surprise. Revenue reached 1.49 million, compared to an expected 2.55 million, with a -41.41% difference. The market reacted with a -18.66% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.21 USD, with revenue projected to reach 5.89 million USD, implying an increase of 162.50% EPS, and increase of 294.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Citius Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Citius Oncology, Inc. Common Stock reported EPS of -$0.08, beating estimates by 1.96%, and revenue of $1.49M, -41.41% below expectations.
How did the market react to Citius Oncology, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -18.66%, changed from $0.91 before the earnings release to $0.74 the day after.
When is Citius Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Dec 21, 2026.
What are the forecasts for Citius Oncology, Inc. Common Stock's next earnings report?
Based on --
analysts, Citius Oncology, Inc. Common Stock is expected to report EPS of -$0.21 and revenue of $5.89M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.